Literature DB >> 23343395

Issues in women's participation in a phase III community HIV vaccine trial in Thailand.

Jaranit Kaewkungwal1, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Chirasak Khamboonruang, Prayura Kunasol, Pravan Suntharasamai, Swangjai Pungpak, Sirivan Vanijanonta, Valai Bussaratid, Wirach Maek-A-Nantawat, Jittima Dhitavat, Prasert Thongcharoen, Rungrawee Pawarana, Yupa Sabmee, Mike W Benenson, Patricia Morgan, Robert J O'Connell, Jerome Kim.   

Abstract

To assess qualities and outcomes of women participating in a large, community-based HIV vaccine trial, the present study was conducted among female participants of the RV 144 prime-boost trial in Thailand from 2003 to 2009. Qualities of participation refer to complete vaccination, retention, and status change. Outcomes of participation refer to incident rate, adverse event, and participation impact event. A total of 6,334 (38.6%) women participated in the trial, of whom about 50% were classified as low risk and 11% as high risk. About 85% of participants completed four vaccinations and 76% were included in the per-protocol analysis of the on-time vaccination schedule. More women (88%) completed 42 months follow-up compared with men (85%). Women aged 21 and above had more adverse events compared to younger age groups. More women (5%) compared with men (3%) reported participation impact events (PIEs). High-risk women had more PIEs and a higher infection rate compared to the low-risk group. Complete vaccination and retention on last follow-up were more common in married women aged above 21, and being a housewife. Female volunteers showed the same qualities and outcomes of participation as males in the HIV vaccine trial. There was no statistically significant difference in vaccine efficacy between men and women, especially among the high-risk and married women. The study highlighted the important behavioral, social, and cultural issues that could be considered for future HIV vaccine trial designs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23343395      PMCID: PMC3809940          DOI: 10.1089/AID.2012.0265

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  29 in total

1.  Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy.

Authors:  N A Hessol; M Schneider; R M Greenblatt; M Bacon; Y Barranday; S Holman; E Robison; C Williams; M Cohen; K Weber
Journal:  Am J Epidemiol       Date:  2001-09-15       Impact factor: 4.897

2.  Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

Authors:  Judith Currier; Dawn Averitt Bridge; Debbie Hagins; Carmen D Zorrilla; Judith Feinberg; Robert Ryan; Ron Falcon; Alan Tennenberg; Joseph Mrus; Kathleen Squires
Journal:  Ann Intern Med       Date:  2010-09-21       Impact factor: 25.391

3.  HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial.

Authors:  Bradford N Bartholow; Susan Buchbinder; Connie Celum; Vamshidar Goli; Beryl Koblin; Michael Para; Michael Marmor; Richard M Novak; Kenneth Mayer; Catherine Creticos; Patti Orozco-Cronin; Vladimir Popovic; Timothy D Mastro
Journal:  J Acquir Immune Defic Syndr       Date:  2005-05-01       Impact factor: 3.731

4.  Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa.

Authors:  Keren Middelkoop; Landon Myer; Daniella Mark; Sibonisile P Mthimunye; Joalida Smit; Robin Wood; Linda-Gail Bekker
Journal:  J Adolesc Health       Date:  2008-03-06       Impact factor: 5.012

Review 5.  Ethical and practical challenges in implementing informed consent in HIV/AIDS clinical trials in developing or resource-limited countries.

Authors:  Kyriaki Mystakidou; Irene Panagiotou; Stelios Katsaragakis; Eleni Tsilika; Efi Parpa
Journal:  SAHARA J       Date:  2009-09

6.  Increasing participation of women in early phase clinical trials approved by the FDA.

Authors:  Ellen Pinnow; Pellavi Sharma; Ameeta Parekh; Natalie Gevorkian; Kathleen Uhl
Journal:  Womens Health Issues       Date:  2009 Mar-Apr

Review 7.  Population issues in clinical trials.

Authors:  Zab Mosenifar
Journal:  Proc Am Thorac Soc       Date:  2007-05

8.  Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.

Authors:  Rita Poon; Keshav Khanijow; Sphoorti Umarjee; Emmanuel Fadiran; Monica Yu; Lei Zhang; Ameeta Parekh
Journal:  J Womens Health (Larchmt)       Date:  2013-06-14       Impact factor: 2.681

9.  Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa.

Authors:  Hannah Kibuuka; David Guwatudde; Robert Kimutai; Lucas Maganga; Leonard Maboko; Cecilia Watyema; Fredrick Sawe; Douglas Shaffer; Dickson Matsiko; Monica Millard; Nelson Michael; Fred Wabwire-Mangen; Merlin Robb
Journal:  PLoS One       Date:  2009-04-10       Impact factor: 3.240

10.  Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge.

Authors:  Edward Mills; Stephanie Nixon; Sonal Singh; Sonam Dolma; Anjali Nayyar; Sushma Kapoor
Journal:  PLoS Med       Date:  2006-02-21       Impact factor: 11.069

View more
  5 in total

Review 1.  Hidden in plain sight: sex and gender in global pandemics.

Authors:  Eileen P Scully
Journal:  Curr Opin HIV AIDS       Date:  2021-01       Impact factor: 4.283

2.  A randomized trial to assess retention rates using mobile phone reminders versus physical contact tracing in a potential HIV vaccine efficacy population of fishing communities around Lake Victoria, Uganda.

Authors:  Noah Kiwanuka; Juliet Mpendo; Stephen Asiimwe; Julius Ssempiira; Annet Nalutaaya; Betty Nambuusi; Mathias Wambuzi; Brian Kabuubi; Annemarie Namuniina; Frederick Oporia; Annet Nanvubya; Ali Ssetaala
Journal:  BMC Infect Dis       Date:  2018-11-21       Impact factor: 3.090

3.  A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes.

Authors:  Lynda Stranix-Chibanda; Chenchen Yu; Margaret Brewinski Isaacs; Mary Allen; Jessica Andriesen; Stephen R Walsh
Journal:  BMC Infect Dis       Date:  2021-08-11       Impact factor: 3.090

4.  Improving ethical and participatory practice for marginalized populations in biomedical HIV prevention trials: lessons from Thailand.

Authors:  Dan Allman; Melissa Hope Ditmore; Karyn Kaplan
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

5.  Incidence of unintended pregnancy among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis.

Authors:  Frances H Ampt; Lisa Willenberg; Paul A Agius; Matthew Chersich; Stanley Luchters; Megan S C Lim
Journal:  BMJ Open       Date:  2018-09-17       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.